Topiramate in the treatment of partial and generalized epilepsy

Neuropsychiatric Disease and Treatment

Volumn 3, Issue 6, 2007, Pages 811-821

  Faught, Edward ^a,b  

^a UNIVERSITY OF ALABAMA SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

Author keywords

Antiepileptic drugs; Epilepsy; Seizures; Topiramate

Indexed keywords

ACETAZOLAMIDE; AMITRIPTYLINE; BARBITURIC ACID DERIVATIVE; CARBAMAZEPINE; DIAZEPAM; DIHYDROERGOTAMINE; ETHINYLESTRADIOL; LAMOTRIGINE; LITHIUM; OXCARBAZEPINE; PHENYTOIN; PLACEBO; PROPRANOLOL; RISPERIDONE; SUMATRIPTAN; TOPIRAMATE; VALPROIC ACID;

ABNORMAL THINKING; ABSENCE; ACIDEMIA; ADJUVANT THERAPY; AGGRESSION; ANHIDROSIS; ANOREXIA; ANTICONVULSANT ACTIVITY; ARTICLE; ASTHENIA; ATTENTION DISTURBANCE; BEDTIME DOSAGE; BICARBONATE BLOOD LEVEL; BRAIN DISEASE; CENTRAL NERVOUS SYSTEM DISEASE; CLINICAL TRIAL; CLOSED ANGLE GLAUCOMA; COGNITIVE DEFECT; DEPRESSION; DRUG ANTAGONISM; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DOSE COMPARISON; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG ERUPTION; DRUG EXCRETION; DRUG HALF LIFE; DRUG MECHANISM; DRUG MEGADOSE; DRUG METABOLISM; DRUG MONITORING; DRUG OVERDOSE; DRUG POTENTIATION; DRUG PROTEIN BINDING; DRUG TOLERABILITY; DRUG TOLERANCE; DRUG WITHDRAWAL; EPILEPTIC STATE; EVENING DOSAGE; EYE PAIN; FATIGUE; FOCAL EPILEPSY; GENERALIZED EPILEPSY; GLAUCOMA; HUMAN; HYPERAMMONEMIA; HYPERTHERMIA; INFANTILE SPASM; IRRITABILITY; LENNOX GASTAUT SYNDROME; LOW DRUG DOSE; MAXIMUM PLASMA CONCENTRATION; MEMORY DISORDER; MENTAL CONCENTRATION; MENTAL DISEASE; METABOLIC ACIDOSIS; MIGRAINE; MONOTHERAPY; MOOD DISORDER; MYOCLONUS EPILEPSY; MYOPIA; NEPHROLITHIASIS; NEUROPROTECTION; NONHUMAN; PARANOIA; PARESTHESIA; PATIENT EDUCATION; PRENATAL EXPOSURE; PSYCHOSIS; RECOMMENDED DRUG DOSE; SECONDARY GLAUCOMA; SEIZURE; SIDE EFFECT; SOMNOLENCE; SPEECH DISORDER; TERATOGENICITY; TONIC CLONIC SEIZURE; WEIGHT REDUCTION; WEST SYNDROME;

EID: 38149111773     PISSN: 11766328     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (99)

1. Abou-Khalil B. 2000. Topiramate in the long-term management of refractory epilepsy. Topiramate YOL Study Group. Epilepsia, 41 Suppl 1:S72-6.
2. Albsoul-Younes AM, Salem HA, Ajlouni SF, et al. 2004. Topiramate slow dose titration: improved efficacy and tolerability. Pediatr Neurol, 31:349-52.
3. Aldenkamp AP. 2000. Cognitive effects of topiramate, gabapentin, and lamotrigine in healthy young adults. Neurology, 54:271-2.
4. Aldenkamp AP, Baker GA, Mulder OG, et al. 2000. A multicenter, randomized clinical study to evaluate the effect on cognitive function of topiramate compared with valproate as add-on therapy to carbamazepine in patients with partial-onset seizures. Epilepsia, 41:1167-8.
5. Arroyo S, Dodson WE, Privitera MD, et al. 2005. Randomized dose-controlled study of topiramate as first-line therapy in epilepsy. Acta Neurol Scand, 112:214-22.
6. Aykutlu E, Baykan B, Gurses C, et al. 2005. Add-on therapy with topiramate in progressive myoclonic epilepsy. Epilepsy Behav, 6:260-3.
7. Ben-Menachem E, Axelsen M, Johanson EH, et al. 2003. Predictors of weight loss in adults with topiramate-treated epilepsy. Obes Res, 11:556-62.
8. Ben-Menachem E, Henriksen O, Dam M, et al. 1996. Double-blind, placebo-controlled trial of topiramate as add-on therapy in patients with refractory partial seizures. Epilepsia, 37:539-43.
9. Ben-Zeev B, Watemberg N, Augarten A, et al. 2003. Oligohydrosis and hyperthermia: pilot study of a novel topiramate adverse effect. J Child Neurol, 18:254-7.
10. Bialer M, Doose DR, Murthy B, et al. 2004. Pharmacokinetic interactions of topiramate. Clin Pharmacokinet, 43:763-80.
11. Biton V, Bourgeois BF. 2005. Topiramate in patients with juvenile myoclonic epilepsy. Arch Neurol, 62:1705-8.
12. Biton V, Edwards KR, Montouris GD, et al. 2001. Topiramate titration and tolerability. Ann Pharmacother, 35:173-9.
13. Biton V, Montouris GD, Ritter F, et al. 1999. A randomized, placebo-controlled study of topiramate in primary generalized tonic-clonic seizures. Topiramate YTC Study Group. Neurology, 52:1330-7.
14. Bootsma HP, Coolen F, Aldenkamp AP, et al. 2004. Topiramate in clinical practice: long-term experience in patients with refractory epilepsy referred to a tertiary epilepsy center. Epilepsy Behav, 5:380-7.
15. Cerminara C, Seri S, Bombardieri R, et al. 2006. Hypohidrosis during topiramate treatment: a rare and reversible side effect. Pediatr Neurol, 34:392-4.
16. Cheung E, Wong V, Fung CW 2005. Topiramate-valproate-induced hyperammonemic encephalopathy syndrome: case report. J Child Neurol, 20:157-60.
17. Christensen J, Andreasen F, Poulsen JH, et al. 2003. Randomized, concentration-controlled trial of topiramate in refractory focal epilepsy. Neurology, 61:1210-18.
18. Coppola G, Capovilla G, Montagnini A, et al. 2002. Topiramate as add-on drug in severe myoclonic epilepsy in infancy: an Italian multicenter open trial. Epilepsy Research, 49:45-8.
19. Coulter DA, Sombati S, Delorenzo RJ. 1993. Selective effects of topiramate on sustained repetitive firing and spontaneous bursting in cultured hippocampal neurons. Epilepsia, 34:123.
20. Cross JH. 2002. Topiramate monotherapy for childhood absence seizures: an open-lable pilot study. Seizure, 11:406-10.
21. Dodgson SJ, Shank RP, Maryanoff BE. 2000. Topiramate as an inhibitor of carbonic anhydrase isoenzymes. Epilepsia, 41 Suppl 1:S35-9.
22. Dodson WE, Kamin M, Kraut L, et al. 2003. Topiramate titration to response: analysis of individualized therapy study (TRAITS). Epilepsia, 37:615-20.
23. Doose DR, Brodie MJ, Wilson EA, et al. 2003. Topiramate and lamotrigine pharmacokinetics during repetitive monotherapy and combination therapy in epilepsy patients. Epilepsia, 44:917-22.
24. Doose DR, Walker SA, Gisclon LG, et al. 1996. Single-dose pharmacokinetics and effect of food on the bioavailability of topiramate, a novel antiepileptic drug. J Clin Pharmacol, 36:884-91.
25. Doose DR, Wang SS, Padmanabhan M, et al. 2003. Effect of topiramate or carbamazepine on the pharmacokinetics of an oral contraceptive containing norethindrone and ethinyl estradiol in healthy obese and nonobese female subjects. Epilepsia, 44:540-9.
26. Elterman RD, Glauser TA, Wyllie E, et al. 1999. A double-blind, randomized trial of topiramate as adjunctive therapy for partial-onset seizures in children. Topiramate YP Study Group. Neurology, 52:1338-44.
27. Faught E. 1999. Clinical studies of topiramate. Drugs Today (Barc), 35:49-57.
28. Faught E, Limdi N. 2002. Adverse and beneficial side effects of antiepileptic drugs. In Ettinger AB, Devinsky O (eds). Managing epilepsy and co-existing disorders. Boston, Butterworth-Heinemann
29. Faught E, Wilder BJ, Ramsay RE, et al. 1996. Topiramate placebo-controlled dose-ranging trial in refractory partial epilepsy using 200-, 400-, and 600-mg daily dosages. Topiramate YD Study Group. Neurology, 46:1684-90.
30. Fraunfelder FW, Fraunfelder FT, Keates EU. 2004. Topiramate-associated acute, bilateral, secondary angle-closure glaucoma. Ophthalmology, 111:109-11.
31. Garris SS, Oles KS. 2005. Impact of topiramate on serum bicarbonate concentrations in adults. Annals Pharmacother, 39:424-6.
32. Gilliam F, Veloso F, Bomhof MA, et al. 2003. A dose-comparison trial of topiramate as monotherapy in recently diagnosed partial epilepsy. Neurology, 60:196-202.
33. Gisclon LG, Riffits JM, Sica DA, et al. 1993. The pharmacokinetics (PK) of topiramate (T) in subjects with renal impairment (RI) as compared to matched subjects with normal renal function (NRF). Pharmaceutical Research, 10:S397.
34. Glauser TA. 1999. Topiramate. Epilepsia 40 Suppl 5:S71-80.
35. Glauser TA, Clark PO, Strawsburg R. 1998. A pilot study of topiramate in the treatment of infantile spasms. Epilepsia, 39:1324-8.
36. Grosso S, Galimberti D, Fametani MA, et al. 2005. Efficacy and safety of topiramate in infants according to epilepsy syndromes. Seizure, 14:183-90.
37. Gryder DS, Rogawski MA. 2003. Selective antagonism of GluR5 kainate-receptor-mediated synaptic currents by topiramate in rat basolateral. amygdala neurons. J Neuroscience, 23:7069-74.
38. Guberman A, Neto W, Gassman-Mayer C, et al. 2002. Low-dose topiramate in adults with treatment-resistant partial-onset seizures. Acta Neurol Scand, 106:183-9.
39. Guerrini R, Carpay J, Groselj J, et al. 2005. Topiramate monotherapy as broad-spectrum antiepileptic; drug in a naturalistic clinical setting. Seizure, 14:371-80.
40. Hamer HM, Knake S, Schomburg U, et al. 2000. Valproate-induced hyperammonemic encephalopathy in the presence of topiramate. Neurology, 54:230-2.
41. Herrero AI, Del Olmo N, Gonzalez-Escalada JR, et al. 2002. Two new actions of topiramate: inhibition of depolarizing GABA(A)-mediated responses and activation of a potassium conductance. Neuropharmacology, 42:210-20.
42. Hosain SA, Merchant S, Solomon GE, et al. 2006. Topiramate for treatment of infantile spasms. J Child Neurol, 21:17-19.
43. Jansen J, Aldenkamp AP, Majoie M, et al. 2006. Functional MEI reveals declined prefrontal cortex activation in patients with epilepsy on topiramate therapy. Epilepsy Behav, 9:181-5.
44. Johannessen SI. 1997. Pharmacokinetics and interaction profile of topiramate: review and comparison with other newer antiepileptic drugs. Epilepsia, 38 Suppl 1:S18-23.
45. Kanner A, Wuu J, Faught E, et al. 2003. A past psychiatric history may be a risk factor for topiramate-related psychiatric and cognitive adverse events. Epilepsy Behav, 4:548-52.
46. Khan A, Faught E, Gilliam F, et al. 1999. Acute psychotic symptoms induced by topiramate. Seizure, 8:235-7.
47. Koh S, Jensen FE. 2001. Topiramate blocks perinatal hypoxia-induced seizures in rat pups. Ann Neurol, 50:366-72.
48. Korean Topiramate Study Group. 1999. Topiramate in medically intractable partial epilepsies: double-blind placebo-controlled randomized parallel group trial. Epilepsia, 40:1767-74.
49. Kwan P, Brodie M. 2000. Early identification of refractory epilepsy. N Engl J Med, 342:314-19.
50. Latour P, Biraben A, Polard E, et al. 2004. Drug induced encephalopathy in six epileptic patients: topiramate? valproate? or both. Hum Psychopharmacol, 19:193-203.
51. Lee H-W, Jung D-K, Suh C-K, et al. 2006. Cognitive effects of low-dose topiramate monotherapy in epilepsy patients: a 1-year follow-up. Epilepsy Behav, 8:736-41.
52. Lhatoo SD, Wong IC, Polizzi G, et al. 2000. Long-term retention rates of lamotrigine, gabapentin, and topiramate in chronic epilepsy. Epilepsia, 41:1592-6.
53. Loescher W, Schmidt D. 2006. Experimental and clinical evidence for loss of effect (tolerance) during prolonged treatment with antiepileptic drugs. Epilepsia, 47:1253-84.
54. Lofton AL, Klein-Schwartz W. 2005. Evaluation of toxicity of topiramate exposures reported to poison centers. Hum Exp Toxicol, 24:591-5.
55. Longin E, Teich M, Koelfen W, et al. 2002. Topiramate enhances the risk of valproate-associated side effects in three children. Epilepsia, 43:451-4.
56. Majkowski J, Neto W, Wapenaar R, et al. 2005. Time course of adverse events in patients with localization-related epilepsy receiving topiramate added to carbamazepine. Epilepsia, 46:648-53.
57. Marson AG, Al-Kharusi AM, Alwaidh M, et al. 2007a. The SANAD study of effectiveness of carbamazepine, gabapentin, lamotrigine, oxcarbazepine, or topiramate for treatment of partial epilepsy: an unblinded randomised controlled trial. Lancet, 369:1000-15.
58. Marson AG, Al-Kharusi AM, Alwaidh M, et al. 2007b. The SANAD study of effectiveness of valproate, lamotrigine, or topiramate for generalised and unclassifiable epilepsy: an unblinded randomised controlled trial. Lancet, 369:1016-26.
59. Maryanoff BE, Nortey SO, Gardocki JF, et al. 1987. Anticonvulsant O-alkyl sulfamates. 2, 3:4, 5-Bis-O-(l-methylethylidene)-beta-D-fructopyranose sulfamate and related compounds. J Med Chem, 30:880-7.
60. Mclean MJ, Bukhari AA, Wamil AW 2000. Effects of topiramate on sodium-dependent action-potential firing by mouse spinal cord neurons in cell culture. Epilepsia, 41 Suppl 1: S21-4.
61. Meador KJ, Loring DW, Hulihan JF, et al. 2003. Differential cognitive and behavioral effects of topiramate and valproate. Neurology, 60:1483-8.
62. Meador KJ, Loring DW, Vahle VJ, et al. 2005. Cognitive and behavioral effects of lamotrigine and topiramate in healthy volunteers. Neurology, 64:2108-14.
63. Mikaeloff Y, De Saint-Martin A, Mancini J, et al. 2003. Topiramate: efficacy and tolerability in children according to epilepsy syndromes. Epilepsy Res, 53:225-32.
64. Mula M, Trimble MR, Thompson P, et al. 2003. Topiramate and word-finding difficulties in patients with epilepsy. Neurology, 60:1104-7.
65. Nakatsuka T, Komatsu T, Fujii T. 1992. Axial skeletal malformations induced by acetazolamide in rabbits. Teratology, 45:629-36.
66. Naritoku DK, Hulihan JF, Schwarzman LK, et al. 2005. Effect of cotherapy reduction on tolerability of epilepsy add-on therapy: a randomized controlled trial. Ann Pharmacother, 39:418-23.
67. Neurologics, Ortho-Mcneil Pharmaceutical Inc. 2006. TOPAMAX prescribing information. URL: http://www.topamax-epilepsy.com/utilities/images/ tpamax.pdf#zoom=100
68. Niebauer M, Gruenthal M. 1999. Topiramate reduces neuronal injury after experimental status epilepticus. Brain Res, 837:263-9.
69. Nieto-Barrera M, Candau R, Nieto-Jimenez M, et al. 2000. Topiramate in the treatment of severe myoclonic epilepsy in infancy. Seizure, 9:590-4.
70. Perucca E. 1997. A pharmacological and clinical review on topiramate, a new antiepileptic drug. Pharmacol Res, 35:241-56.
71. Privitera M, Fincham R, Penry J, et al. 1996. Topiramate placebo-controlled dose-ranging trial in refractory partial epilepsy using 600-, 800-, and 1,000-mg daily dosages. Topiramate YE Study Group. Neurology, 46:1678-83.
72. Privitera MD, Brodie MJ, Mattson RH, et al. 2003. Topiramate, carbamazepine and valproate monotherapy: double-blind comparison in newly diagnosed epilepsy. Acta Neurol Scand, 107:165-75.
73. Reife R, Pledger G, Wu SC. 2000. Topiramate as add-on therapy: pooled analysis of randomized controlled trials in adults. Epilepsia, 41 Suppl 1:S66-71.
74. Rigoulot M, Boehrer A, Nehlig A. 2003. Effects of topiramate in two models of genetically-determined generalized epilepsy, the GAERS and the audiogenic Wister AS. Epilepsia, 44:14-19.
75. Rosenfeld WE, Doose DR, Walker SA, et al. 1999. A study of topiramate pharmacokinetics and tolerability in children withh epilepsy. Pediatric Neurology, 20:339-44.
76. Rosenfeld WE, Doose DR, Walker SA, et al. 1997. Effect of topiramate on the pharmacokinetics of an oral contraceptive containing norethindrone and ethinyl estradiol in patients with epilepsy. Epilepsia, 38:317-23.
77. Rosenfeld WE, Slater J. 2002. Characterization of topiramate-associated weight changes in adults with epilepsy. Epilepsia, 43 (Suppl 7):220-1.
78. Sachdeo R, Wasserstein A, Mesenbrink P, et al. 2002. Effects of oxcarbazepine on sodium concentration and water handling. Ann Neurol, 51:613-20.
79. Sachdeo RC, Glauser TA., Ritter F, et al. 1999. A double-blind, randomized trial of topirarnate in Lennox-Gastaut syndrome. Topiramate YL Study Group. Neurology, 52:1882-7.
80. Sachdeo RC, Reife RA, Lim P, et al. 1997. Topiramate monotherapy for partial onset seizures. Epilepsia, 38:294-300.
81. Sachdeo RC, Sachdeo SK, Levy RH, et al. 2002. Topiramate and phenytoin pharmacokinetics during repetitive monotherapy and combination therapy to epileptic patients. Epilepsia, 43:691-6.
82. Sachdeo RC, Sachdeo SK, Walker SA, et al. 1996. Steady-state pharmacokinetics of topiramate and carbamazepine in patients with epilepsy during monotherapy and concomitant therapy. Epilepsia, 37:774-80.
83. Schneiderman JH. 1998. Topiramate: pharmacokinetics and pharmacodynamics. Can J Neurol Sci, 25:S3-5.
84. Shank RP, Gardocki JF, Streeter AJ, et al. 2000. An overview of the preclinical aspects of topiramate: pharmacology, pharmacokinetics, and mechanism of action. Epilepsia, 41 Suppl 1:S3-9.
85. Shank RP, Gardocki JF, Vaught JL, et al. 1994. Topiramate: preclinical evaluation of structurally novel anticonvulsant. Epilepsia, 35:450-60.
86. Sharief M, Viteri C, Ben-Menachem E, et al. 1996. Double-blind, placebo-controlled study of topiramate in patients with refractory partial epilepsy. Epilepsy Res, 25:217-24.
87. Shorvon S. 1996. Safety of topiramate: adverse events and relationship to dosing. Epilepsia, 37:S18-22.
88. Sousa Pda S, De Araujo Filho GM, Garzon E, et al. 2005. Topiramate for the treatment of juvenile myoclonic epilepsy. Arq Neuropsiquiatr, 63:733-7.
89. Tassinari CA, Michelucci R, Chauvel P, et al. 1996. Double-blind, placebo-controlled trial of topiramate (600 mg daily) for the treatment of refractory partial epilepsy. Epilepsia, 37:763-8.
90. Tatum WOT, French JA, Faught E, et al. 2001. Postmarketing experience with topiramate and cognition. Epilepsia, 42:1134-40.
91. Thijs J, Verhelst H, Van Coster R. 2001. Retrospective study of topiramate in a paediatric population with intractable epilepsy showing promising effects in the West Syndrome patients. Acta Neurol Belg, 101:171-6.
92. Towne AR, Garnett LK, Waterhouse EJ, et al. 2003. The use of topiramate in refractory status epilepticus. Neurology, 60:332-4.
93. Valencia I, Forts C, Kothare SV, et al. 2005. Efficacy and tolerability of topiramate in children younger than 2 years old. J Child Neurol, 20:667-9.
94. Waugh J, Goa KL. 2003. Topiramate: as monotherapy in newly diagnosed epilepsy. CNS Drugs, 17:985-92.
95. Wauquier A, Zhou S. 1996. Topiramate: a potent anticonvulsant in the amygdala-kindled rat. Epilepsy Res, 24:73-7.
96. White HS, Brown SD, Woodhead JH, et al. 1997. Topiramate enhances GABA-mediated chloride flux and GABA-evoked chloride currents in murine brain neurons and increases seizure threshold. Epilepsy Res, 28:167-79.
97. White HS, Brown SD, Woodhead JH, et al. 2000. Topiramate modulates GABA-evoked currents in murine cortical neurons by a nonbenzodiazepine mechanism. Epilepsia, 41 Suppl 1:S17-20.
98. Wu WN, Heebner JB, Streeter AJ. 1994. Evaluation of the absorption, excretion, pharmacokinetics and metabolism of the anticonvulsant topiramate in healthy men. Pharmaceutical Research, 11:S336.
99. Zhang Y, Velumian AA, Jones OT, et al. 2000. Modulation of high-voltage-activated calcium channels in dentate granule cells by topiramate. Epilepsia, 41:S52-60.